| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Global Health | 12 | 2020 | 657 | 2.350 |
Why?
|
| HIV Infections | 26 | 2023 | 2134 | 2.350 |
Why?
|
| Pediatrics | 16 | 2020 | 1141 | 2.160 |
Why?
|
| Acquired Immunodeficiency Syndrome | 5 | 2023 | 362 | 1.840 |
Why?
|
| Preceptorship | 3 | 2019 | 35 | 1.440 |
Why?
|
| Pneumococcal Infections | 16 | 2007 | 241 | 1.370 |
Why?
|
| Anti-HIV Agents | 7 | 2018 | 350 | 1.260 |
Why?
|
| Attitude of Health Personnel | 4 | 2019 | 918 | 1.150 |
Why?
|
| Ehrlichiosis | 5 | 2007 | 20 | 0.940 |
Why?
|
| Streptococcus pneumoniae | 22 | 2011 | 330 | 0.880 |
Why?
|
| International Cooperation | 3 | 2017 | 323 | 0.770 |
Why?
|
| Salmonella Infections | 6 | 2004 | 40 | 0.760 |
Why?
|
| Infant | 65 | 2018 | 13310 | 0.750 |
Why?
|
| Health Resources | 4 | 2019 | 168 | 0.740 |
Why?
|
| Meningitis, Bacterial | 6 | 2011 | 89 | 0.720 |
Why?
|
| Child | 71 | 2023 | 29154 | 0.710 |
Why?
|
| Salmonella | 7 | 2004 | 35 | 0.700 |
Why?
|
| Child, Preschool | 60 | 2019 | 16273 | 0.690 |
Why?
|
| International Educational Exchange | 1 | 2019 | 17 | 0.680 |
Why?
|
| Sarcoma, Kaposi | 6 | 2019 | 187 | 0.680 |
Why?
|
| Organizational Innovation | 1 | 2018 | 68 | 0.650 |
Why?
|
| Problem-Based Learning | 1 | 2018 | 78 | 0.630 |
Why?
|
| Anti-Bacterial Agents | 24 | 2016 | 2992 | 0.630 |
Why?
|
| Professionalism | 1 | 2018 | 52 | 0.620 |
Why?
|
| AIDS-Related Opportunistic Infections | 2 | 2013 | 163 | 0.620 |
Why?
|
| Haemophilus influenzae | 5 | 2011 | 144 | 0.620 |
Why?
|
| Pneumococcal Vaccines | 5 | 2005 | 161 | 0.580 |
Why?
|
| Perception | 1 | 2018 | 350 | 0.550 |
Why?
|
| Tuberculosis | 2 | 2020 | 548 | 0.550 |
Why?
|
| Time-to-Treatment | 1 | 2018 | 292 | 0.550 |
Why?
|
| Curriculum | 6 | 2020 | 860 | 0.550 |
Why?
|
| Bacteremia | 9 | 2015 | 689 | 0.540 |
Why?
|
| Developing Countries | 2 | 2017 | 315 | 0.540 |
Why?
|
| Students, Medical | 2 | 2018 | 399 | 0.540 |
Why?
|
| Internship and Residency | 6 | 2020 | 1375 | 0.530 |
Why?
|
| Arkansas | 15 | 2004 | 58 | 0.520 |
Why?
|
| Haemophilus Infections | 3 | 2003 | 103 | 0.490 |
Why?
|
| Zika Virus | 1 | 2016 | 144 | 0.490 |
Why?
|
| HIV | 2 | 2012 | 229 | 0.480 |
Why?
|
| Zika Virus Infection | 1 | 2016 | 166 | 0.470 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2013 | 84 | 0.450 |
Why?
|
| Malawi | 11 | 2019 | 378 | 0.440 |
Why?
|
| Tanzania | 4 | 2020 | 68 | 0.430 |
Why?
|
| Humans | 128 | 2023 | 261506 | 0.430 |
Why?
|
| Academies and Institutes | 1 | 2012 | 95 | 0.420 |
Why?
|
| Health Personnel | 3 | 2017 | 625 | 0.420 |
Why?
|
| HIV Antibodies | 1 | 2012 | 102 | 0.420 |
Why?
|
| HIV Seropositivity | 1 | 2012 | 144 | 0.400 |
Why?
|
| Antiretroviral Therapy, Highly Active | 5 | 2016 | 317 | 0.400 |
Why?
|
| Coinfection | 1 | 2013 | 189 | 0.400 |
Why?
|
| Rocky Mountain Spotted Fever | 3 | 2007 | 7 | 0.400 |
Why?
|
| Hepatitis B virus | 1 | 2013 | 217 | 0.400 |
Why?
|
| Meningitis, Cryptococcal | 1 | 2011 | 25 | 0.400 |
Why?
|
| Delivery of Health Care | 1 | 2018 | 860 | 0.390 |
Why?
|
| Africa South of the Sahara | 4 | 2020 | 101 | 0.390 |
Why?
|
| Hepatitis B | 1 | 2013 | 258 | 0.380 |
Why?
|
| Cephalosporins | 8 | 2002 | 148 | 0.370 |
Why?
|
| Cross Infection | 3 | 2004 | 544 | 0.370 |
Why?
|
| DNA Fingerprinting | 5 | 2007 | 167 | 0.370 |
Why?
|
| Polymerase Chain Reaction | 6 | 2012 | 3203 | 0.360 |
Why?
|
| DNA, Viral | 1 | 2012 | 694 | 0.360 |
Why?
|
| Microbial Sensitivity Tests | 13 | 2011 | 994 | 0.360 |
Why?
|
| Drug Resistance, Microbial | 9 | 2016 | 218 | 0.360 |
Why?
|
| Teaching | 3 | 2019 | 243 | 0.360 |
Why?
|
| Male | 68 | 2020 | 123000 | 0.360 |
Why?
|
| Infant, Newborn | 26 | 2012 | 8223 | 0.350 |
Why?
|
| Adolescent | 34 | 2020 | 31252 | 0.350 |
Why?
|
| Female | 73 | 2020 | 141928 | 0.340 |
Why?
|
| Clostridium Infections | 1 | 2012 | 252 | 0.340 |
Why?
|
| Lesotho | 4 | 2019 | 17 | 0.340 |
Why?
|
| Physicians | 3 | 2016 | 882 | 0.330 |
Why?
|
| Penicillin Resistance | 6 | 2005 | 69 | 0.330 |
Why?
|
| Ehrlichia chaffeensis | 4 | 2006 | 12 | 0.320 |
Why?
|
| Focus Groups | 2 | 2019 | 256 | 0.320 |
Why?
|
| Meningococcal Vaccines | 2 | 2004 | 31 | 0.310 |
Why?
|
| Streptococcal Infections | 5 | 2015 | 280 | 0.310 |
Why?
|
| Serotyping | 13 | 2007 | 166 | 0.290 |
Why?
|
| Meningococcal Infections | 2 | 2006 | 21 | 0.290 |
Why?
|
| Education, Medical, Continuing | 1 | 2008 | 251 | 0.280 |
Why?
|
| Malaria | 1 | 2006 | 92 | 0.270 |
Why?
|
| Medication Adherence | 1 | 2010 | 492 | 0.270 |
Why?
|
| Africa | 4 | 2016 | 142 | 0.270 |
Why?
|
| Neisseria meningitidis | 3 | 2006 | 23 | 0.270 |
Why?
|
| Retrospective Studies | 31 | 2019 | 37905 | 0.260 |
Why?
|
| Ambulatory Care Facilities | 2 | 2018 | 289 | 0.260 |
Why?
|
| Blastomycosis | 2 | 1996 | 17 | 0.250 |
Why?
|
| Schools, Medical | 2 | 2017 | 132 | 0.250 |
Why?
|
| Health Facility Closure | 1 | 2004 | 8 | 0.240 |
Why?
|
| Viral Load | 2 | 2018 | 493 | 0.240 |
Why?
|
| Cooperative Behavior | 2 | 2017 | 313 | 0.240 |
Why?
|
| Cephalosporin Resistance | 5 | 2001 | 16 | 0.230 |
Why?
|
| Faculty, Medical | 2 | 2020 | 289 | 0.230 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 7 | 2007 | 128 | 0.230 |
Why?
|
| Anti-Retroviral Agents | 2 | 2016 | 148 | 0.230 |
Why?
|
| Health Services Accessibility | 3 | 2018 | 761 | 0.220 |
Why?
|
| Bacterial Infections | 3 | 2016 | 479 | 0.220 |
Why?
|
| Pseudomonas Infections | 1 | 2004 | 156 | 0.210 |
Why?
|
| Career Mobility | 2 | 2020 | 95 | 0.210 |
Why?
|
| Cat-Scratch Disease | 3 | 2000 | 35 | 0.210 |
Why?
|
| Herpesvirus 8, Human | 2 | 2019 | 102 | 0.210 |
Why?
|
| Malnutrition | 4 | 2014 | 218 | 0.210 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2004 | 233 | 0.210 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2004 | 273 | 0.210 |
Why?
|
| Fellowships and Scholarships | 2 | 2016 | 390 | 0.200 |
Why?
|
| Infection Control | 1 | 2004 | 270 | 0.200 |
Why?
|
| Doxycycline | 4 | 2007 | 178 | 0.200 |
Why?
|
| Seroepidemiologic Studies | 4 | 2013 | 129 | 0.200 |
Why?
|
| Salmonella Food Poisoning | 2 | 1998 | 4 | 0.200 |
Why?
|
| Infectious Disease Transmission, Vertical | 2 | 2012 | 234 | 0.200 |
Why?
|
| Splenectomy | 1 | 2002 | 158 | 0.200 |
Why?
|
| Bartonella Infections | 1 | 2000 | 6 | 0.200 |
Why?
|
| Tularemia | 2 | 1998 | 12 | 0.200 |
Why?
|
| Adult | 21 | 2020 | 77950 | 0.190 |
Why?
|
| Bartonella henselae | 1 | 2000 | 23 | 0.190 |
Why?
|
| Whooping Cough | 2 | 2004 | 62 | 0.190 |
Why?
|
| Referral and Consultation | 1 | 2006 | 899 | 0.190 |
Why?
|
| Specialization | 2 | 2015 | 130 | 0.190 |
Why?
|
| Administrative Personnel | 1 | 2020 | 35 | 0.180 |
Why?
|
| Patient Admission | 3 | 1998 | 220 | 0.180 |
Why?
|
| Citrobacter | 1 | 1999 | 22 | 0.180 |
Why?
|
| Education, Medical | 2 | 2017 | 331 | 0.180 |
Why?
|
| Alanine Transaminase | 2 | 2013 | 227 | 0.180 |
Why?
|
| Poultry | 2 | 1996 | 10 | 0.180 |
Why?
|
| Spleen | 1 | 2002 | 676 | 0.180 |
Why?
|
| Sepsis | 3 | 2011 | 652 | 0.180 |
Why?
|
| Program Evaluation | 3 | 2018 | 597 | 0.170 |
Why?
|
| Education, Medical, Graduate | 2 | 2015 | 671 | 0.170 |
Why?
|
| Hospitalization | 6 | 2013 | 2083 | 0.170 |
Why?
|
| Drug Utilization | 2 | 2016 | 179 | 0.170 |
Why?
|
| Enterobacteriaceae Infections | 1 | 1999 | 69 | 0.170 |
Why?
|
| Mentoring | 1 | 2020 | 87 | 0.170 |
Why?
|
| Qualitative Research | 2 | 2019 | 556 | 0.170 |
Why?
|
| Environmental Microbiology | 1 | 1999 | 22 | 0.170 |
Why?
|
| Clinical Competence | 2 | 2018 | 1270 | 0.170 |
Why?
|
| Efficiency, Organizational | 1 | 2019 | 88 | 0.170 |
Why?
|
| Catheterization, Central Venous | 1 | 2002 | 354 | 0.160 |
Why?
|
| Salmonella typhimurium | 3 | 2006 | 70 | 0.160 |
Why?
|
| CD4 Lymphocyte Count | 3 | 2013 | 297 | 0.160 |
Why?
|
| Botswana | 3 | 2016 | 87 | 0.160 |
Why?
|
| Program Development | 1 | 2020 | 261 | 0.160 |
Why?
|
| Incidence | 10 | 2007 | 5673 | 0.160 |
Why?
|
| Reference Standards | 2 | 2018 | 339 | 0.160 |
Why?
|
| Models, Organizational | 1 | 2018 | 76 | 0.160 |
Why?
|
| Antibodies, Bacterial | 4 | 2003 | 380 | 0.160 |
Why?
|
| Fever of Unknown Origin | 1 | 1998 | 63 | 0.150 |
Why?
|
| Ceftizoxime | 1 | 1997 | 3 | 0.150 |
Why?
|
| Interleukin-6 | 2 | 2019 | 1038 | 0.150 |
Why?
|
| Immunization, Passive | 1 | 1998 | 172 | 0.150 |
Why?
|
| Authorship | 1 | 2017 | 53 | 0.150 |
Why?
|
| Canada | 1 | 2018 | 429 | 0.150 |
Why?
|
| Herpesviridae Infections | 1 | 2018 | 175 | 0.150 |
Why?
|
| Internationality | 1 | 2018 | 208 | 0.150 |
Why?
|
| Respiratory Syncytial Virus Infections | 2 | 1998 | 427 | 0.150 |
Why?
|
| Hospitals, Pediatric | 4 | 2013 | 773 | 0.150 |
Why?
|
| Egg Shell | 1 | 1996 | 2 | 0.150 |
Why?
|
| Bibliometrics | 1 | 2017 | 71 | 0.150 |
Why?
|
| Salmonella enteritidis | 1 | 1996 | 7 | 0.150 |
Why?
|
| Drug Resistance, Multiple | 1 | 1997 | 204 | 0.150 |
Why?
|
| Learning | 2 | 2018 | 403 | 0.150 |
Why?
|
| Eggs | 1 | 1996 | 24 | 0.140 |
Why?
|
| Epiglottitis | 1 | 1996 | 16 | 0.140 |
Why?
|
| AIDS Serodiagnosis | 2 | 2013 | 61 | 0.140 |
Why?
|
| Population Surveillance | 4 | 2006 | 627 | 0.140 |
Why?
|
| Blastomyces | 1 | 1996 | 8 | 0.140 |
Why?
|
| Community Health Services | 1 | 2017 | 126 | 0.140 |
Why?
|
| Lost to Follow-Up | 1 | 2016 | 34 | 0.140 |
Why?
|
| Learning Curve | 1 | 2016 | 68 | 0.140 |
Why?
|
| Risk Factors | 13 | 2013 | 17523 | 0.140 |
Why?
|
| Foot Diseases | 1 | 1996 | 52 | 0.140 |
Why?
|
| Fluoroquinolones | 1 | 2016 | 126 | 0.140 |
Why?
|
| Ceftriaxone | 6 | 2007 | 67 | 0.140 |
Why?
|
| Fever | 2 | 2000 | 497 | 0.140 |
Why?
|
| Lice Infestations | 1 | 2015 | 1 | 0.130 |
Why?
|
| Pediculus | 1 | 2015 | 1 | 0.130 |
Why?
|
| Pediatric Emergency Medicine | 1 | 2016 | 41 | 0.130 |
Why?
|
| Rickettsia rickettsii | 2 | 2007 | 4 | 0.130 |
Why?
|
| Macrolides | 2 | 2006 | 62 | 0.130 |
Why?
|
| Medication Errors | 1 | 2017 | 174 | 0.130 |
Why?
|
| Staff Development | 2 | 2017 | 61 | 0.130 |
Why?
|
| United States | 13 | 2018 | 15433 | 0.130 |
Why?
|
| Drug Resistance, Bacterial | 4 | 2006 | 418 | 0.130 |
Why?
|
| Pneumonia | 2 | 2011 | 751 | 0.130 |
Why?
|
| Extracorporeal Circulation | 1 | 1995 | 43 | 0.130 |
Why?
|
| Urinary Tract Infections | 1 | 1999 | 321 | 0.130 |
Why?
|
| Pharynx | 2 | 2006 | 153 | 0.130 |
Why?
|
| Neuromuscular Diseases | 1 | 1995 | 63 | 0.130 |
Why?
|
| Immunocompromised Host | 3 | 2007 | 698 | 0.130 |
Why?
|
| Research | 1 | 2017 | 415 | 0.130 |
Why?
|
| Streptococcus pyogenes | 2 | 2006 | 119 | 0.130 |
Why?
|
| Buruli Ulcer | 1 | 2014 | 2 | 0.120 |
Why?
|
| Heart Transplantation | 1 | 2001 | 908 | 0.120 |
Why?
|
| Emergency Medicine | 1 | 2016 | 134 | 0.120 |
Why?
|
| Publishing | 1 | 2017 | 220 | 0.120 |
Why?
|
| Pneumonia, Pneumococcal | 4 | 2007 | 74 | 0.120 |
Why?
|
| Professional Competence | 2 | 2015 | 136 | 0.120 |
Why?
|
| Antitubercular Agents | 2 | 2014 | 318 | 0.120 |
Why?
|
| Endocarditis | 1 | 2015 | 125 | 0.120 |
Why?
|
| Stevens-Johnson Syndrome | 1 | 2013 | 21 | 0.120 |
Why?
|
| Sexually Transmitted Diseases | 1 | 1994 | 106 | 0.120 |
Why?
|
| Drug Administration Schedule | 4 | 2012 | 3472 | 0.120 |
Why?
|
| Quality Assurance, Health Care | 1 | 2018 | 585 | 0.120 |
Why?
|
| False Negative Reactions | 2 | 2012 | 275 | 0.120 |
Why?
|
| Hand Disinfection | 1 | 2012 | 19 | 0.110 |
Why?
|
| Medical Records | 2 | 2007 | 415 | 0.110 |
Why?
|
| Salicylates | 1 | 2013 | 59 | 0.110 |
Why?
|
| Antidiarrheals | 1 | 2013 | 37 | 0.110 |
Why?
|
| Syringes | 1 | 2013 | 42 | 0.110 |
Why?
|
| Bismuth | 1 | 2013 | 75 | 0.110 |
Why?
|
| Penicillins | 5 | 2007 | 143 | 0.110 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2012 | 70 | 0.110 |
Why?
|
| Arachnid Vectors | 2 | 2006 | 10 | 0.110 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2012 | 78 | 0.110 |
Why?
|
| Cerebrospinal Fluid | 2 | 2011 | 120 | 0.110 |
Why?
|
| Meningitis, Pneumococcal | 3 | 1998 | 36 | 0.110 |
Why?
|
| Primary Prevention | 1 | 1994 | 255 | 0.110 |
Why?
|
| Food Microbiology | 4 | 2002 | 26 | 0.110 |
Why?
|
| Interdisciplinary Communication | 1 | 2014 | 280 | 0.110 |
Why?
|
| Ticks | 2 | 2006 | 32 | 0.110 |
Why?
|
| Mycobacterium Infections | 2 | 2005 | 49 | 0.110 |
Why?
|
| Antigens, Bacterial | 1 | 1994 | 354 | 0.100 |
Why?
|
| Organometallic Compounds | 1 | 2013 | 191 | 0.100 |
Why?
|
| Tuberculin Test | 1 | 1993 | 132 | 0.100 |
Why?
|
| Histoplasmosis | 1 | 1992 | 74 | 0.100 |
Why?
|
| Southeastern United States | 3 | 2007 | 54 | 0.100 |
Why?
|
| Opsonin Proteins | 1 | 1991 | 15 | 0.100 |
Why?
|
| Cryptococcus | 1 | 2011 | 8 | 0.100 |
Why?
|
| Cross-Sectional Studies | 4 | 2015 | 4314 | 0.100 |
Why?
|
| Face | 1 | 2014 | 273 | 0.100 |
Why?
|
| Vaccines, Conjugate | 3 | 2005 | 76 | 0.100 |
Why?
|
| Receptors, Complement | 1 | 1991 | 48 | 0.100 |
Why?
|
| Phagocytosis | 2 | 1994 | 260 | 0.100 |
Why?
|
| Staphylococcus epidermidis | 1 | 1991 | 61 | 0.100 |
Why?
|
| Role | 1 | 2011 | 48 | 0.100 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2016 | 573 | 0.100 |
Why?
|
| Hospitals | 2 | 2011 | 485 | 0.100 |
Why?
|
| Prevalence | 3 | 2013 | 3260 | 0.100 |
Why?
|
| Social Responsibility | 1 | 2011 | 92 | 0.100 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 1993 | 247 | 0.100 |
Why?
|
| Opportunistic Infections | 1 | 1992 | 223 | 0.090 |
Why?
|
| Pilot Projects | 3 | 2018 | 2803 | 0.090 |
Why?
|
| Ammonia | 1 | 1990 | 88 | 0.090 |
Why?
|
| Prospective Studies | 9 | 2019 | 12873 | 0.090 |
Why?
|
| Cytokines | 1 | 2019 | 2809 | 0.090 |
Why?
|
| Diet | 1 | 1998 | 1440 | 0.090 |
Why?
|
| Medicine | 2 | 2016 | 137 | 0.090 |
Why?
|
| Lung Diseases | 1 | 1996 | 717 | 0.090 |
Why?
|
| Cefotaxime | 4 | 2001 | 34 | 0.090 |
Why?
|
| Ambulatory Care | 2 | 2013 | 554 | 0.090 |
Why?
|
| Health Policy | 1 | 2012 | 291 | 0.090 |
Why?
|
| Herpes Simplex | 1 | 1990 | 95 | 0.090 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2003 | 419 | 0.090 |
Why?
|
| Leprostatic Agents | 1 | 2009 | 3 | 0.090 |
Why?
|
| Biomedical Research | 1 | 2017 | 806 | 0.090 |
Why?
|
| Adoption | 1 | 2009 | 14 | 0.090 |
Why?
|
| Young Adult | 4 | 2018 | 21445 | 0.090 |
Why?
|
| Communicable Disease Control | 1 | 2011 | 175 | 0.090 |
Why?
|
| Caregivers | 2 | 2016 | 677 | 0.090 |
Why?
|
| Leprosy | 1 | 2009 | 33 | 0.080 |
Why?
|
| Heptavalent Pneumococcal Conjugate Vaccine | 2 | 2004 | 28 | 0.080 |
Why?
|
| Neutrophils | 2 | 1998 | 835 | 0.080 |
Why?
|
| Time Factors | 4 | 2016 | 12926 | 0.080 |
Why?
|
| Otitis Media | 2 | 2005 | 65 | 0.080 |
Why?
|
| Mass Screening | 2 | 2013 | 1509 | 0.080 |
Why?
|
| Inpatients | 1 | 2013 | 678 | 0.080 |
Why?
|
| Administration, Oral | 3 | 2016 | 1544 | 0.080 |
Why?
|
| Hypoalbuminemia | 1 | 2007 | 46 | 0.080 |
Why?
|
| Sensitivity and Specificity | 4 | 2004 | 4971 | 0.070 |
Why?
|
| Pregnancy Complications | 1 | 2012 | 526 | 0.070 |
Why?
|
| Aspartate Aminotransferases | 1 | 2007 | 153 | 0.070 |
Why?
|
| Molecular Epidemiology | 2 | 2006 | 246 | 0.070 |
Why?
|
| Plasmodium | 1 | 2006 | 8 | 0.070 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2011 | 426 | 0.070 |
Why?
|
| Leukopenia | 1 | 2007 | 151 | 0.070 |
Why?
|
| Minisatellite Repeats | 1 | 2006 | 51 | 0.070 |
Why?
|
| Chi-Square Distribution | 2 | 2001 | 1323 | 0.070 |
Why?
|
| Geography | 1 | 2006 | 140 | 0.070 |
Why?
|
| Antimalarials | 1 | 2006 | 55 | 0.070 |
Why?
|
| Anaplasma phagocytophilum | 1 | 2006 | 2 | 0.070 |
Why?
|
| Gentamicins | 2 | 1998 | 90 | 0.070 |
Why?
|
| Hyponatremia | 1 | 2007 | 82 | 0.070 |
Why?
|
| Demography | 1 | 2007 | 435 | 0.070 |
Why?
|
| Ketolides | 1 | 2005 | 4 | 0.070 |
Why?
|
| Nevirapine | 2 | 2016 | 17 | 0.070 |
Why?
|
| Abdominal Abscess | 1 | 2005 | 26 | 0.070 |
Why?
|
| Surveys and Questionnaires | 2 | 2015 | 5687 | 0.070 |
Why?
|
| Hospital Mortality | 1 | 2011 | 1274 | 0.070 |
Why?
|
| Follow-Up Studies | 6 | 2007 | 14889 | 0.070 |
Why?
|
| Cellulitis | 2 | 2007 | 72 | 0.070 |
Why?
|
| Lymphopenia | 1 | 2007 | 199 | 0.060 |
Why?
|
| Morbidity | 2 | 2006 | 397 | 0.060 |
Why?
|
| Water Microbiology | 1 | 2004 | 22 | 0.060 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 2 | 2013 | 72 | 0.060 |
Why?
|
| Equipment Design | 2 | 2013 | 1204 | 0.060 |
Why?
|
| Severity of Illness Index | 4 | 2016 | 4320 | 0.060 |
Why?
|
| Blood-Borne Pathogens | 1 | 2004 | 13 | 0.060 |
Why?
|
| Recurrence | 4 | 2007 | 4758 | 0.060 |
Why?
|
| Public Health Practice | 1 | 2004 | 22 | 0.060 |
Why?
|
| Age Distribution | 3 | 2007 | 698 | 0.060 |
Why?
|
| Genotype | 4 | 2007 | 4109 | 0.060 |
Why?
|
| Confidence Intervals | 3 | 2007 | 756 | 0.060 |
Why?
|
| Peritoneal Dialysis | 1 | 2005 | 125 | 0.060 |
Why?
|
| Infant, Low Birth Weight | 1 | 2004 | 181 | 0.060 |
Why?
|
| Blotting, Southern | 1 | 2003 | 406 | 0.060 |
Why?
|
| Disease Outbreaks | 2 | 2004 | 415 | 0.060 |
Why?
|
| Texas | 1 | 2014 | 6311 | 0.060 |
Why?
|
| Endocarditis, Bacterial | 1 | 2004 | 128 | 0.050 |
Why?
|
| Treatment Outcome | 13 | 2016 | 32848 | 0.050 |
Why?
|
| Campylobacter | 1 | 2002 | 25 | 0.050 |
Why?
|
| Campylobacter Infections | 1 | 2002 | 36 | 0.050 |
Why?
|
| Animals | 8 | 2015 | 59536 | 0.050 |
Why?
|
| Silver Sulfadiazine | 1 | 2002 | 15 | 0.050 |
Why?
|
| Listeria monocytogenes | 1 | 2002 | 52 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 1990 | 715 | 0.050 |
Why?
|
| Catheters, Indwelling | 1 | 2005 | 374 | 0.050 |
Why?
|
| Epidemiologic Studies | 1 | 2002 | 60 | 0.050 |
Why?
|
| Reproducibility of Results | 1 | 2012 | 6009 | 0.050 |
Why?
|
| Ethiopia | 2 | 2014 | 24 | 0.050 |
Why?
|
| Socioeconomic Factors | 2 | 2016 | 1225 | 0.050 |
Why?
|
| Chickens | 1 | 2002 | 523 | 0.050 |
Why?
|
| Biomarkers | 1 | 2013 | 5047 | 0.050 |
Why?
|
| Sex Distribution | 2 | 2007 | 495 | 0.050 |
Why?
|
| Pertussis Vaccine | 2 | 2004 | 28 | 0.050 |
Why?
|
| Vaccination | 2 | 2004 | 1123 | 0.050 |
Why?
|
| Chlorhexidine | 1 | 2002 | 88 | 0.050 |
Why?
|
| Virulence | 1 | 2002 | 323 | 0.050 |
Why?
|
| Bacterial Proteins | 2 | 2006 | 1029 | 0.050 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2002 | 121 | 0.050 |
Why?
|
| Facial Dermatoses | 1 | 2000 | 26 | 0.050 |
Why?
|
| Rifampin | 1 | 2002 | 191 | 0.050 |
Why?
|
| Mastoiditis | 1 | 2000 | 26 | 0.050 |
Why?
|
| Risk Assessment | 3 | 2016 | 6869 | 0.050 |
Why?
|
| Minocycline | 1 | 2002 | 182 | 0.050 |
Why?
|
| Secondary Prevention | 1 | 2001 | 329 | 0.040 |
Why?
|
| Age Factors | 3 | 2016 | 5377 | 0.040 |
Why?
|
| Sequence Analysis, DNA | 2 | 2006 | 2483 | 0.040 |
Why?
|
| Awards and Prizes | 1 | 2020 | 98 | 0.040 |
Why?
|
| Middle Aged | 4 | 2013 | 86204 | 0.040 |
Why?
|
| Prognosis | 4 | 2016 | 21713 | 0.040 |
Why?
|
| Lymphadenopathy | 1 | 2019 | 90 | 0.040 |
Why?
|
| Endemic Diseases | 1 | 2018 | 67 | 0.040 |
Why?
|
| Housing | 1 | 1999 | 61 | 0.040 |
Why?
|
| Sudden Infant Death | 1 | 1998 | 33 | 0.040 |
Why?
|
| Respiration, Artificial | 1 | 2002 | 577 | 0.040 |
Why?
|
| HIV-1 | 2 | 2016 | 653 | 0.040 |
Why?
|
| Francisella tularensis | 1 | 1998 | 19 | 0.040 |
Why?
|
| Bronchoalveolar Lavage | 1 | 1998 | 53 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2001 | 1391 | 0.040 |
Why?
|
| Sulfonamides | 1 | 2007 | 1823 | 0.040 |
Why?
|
| Managed Care Programs | 1 | 1998 | 74 | 0.040 |
Why?
|
| Ehrlichia | 1 | 1997 | 5 | 0.040 |
Why?
|
| Genetic Variation | 2 | 2003 | 2086 | 0.040 |
Why?
|
| Arthritis | 1 | 1998 | 139 | 0.040 |
Why?
|
| Handwriting | 1 | 1997 | 12 | 0.040 |
Why?
|
| Coloring Agents | 1 | 1998 | 234 | 0.040 |
Why?
|
| Developed Countries | 1 | 2017 | 42 | 0.040 |
Why?
|
| Respiratory Syncytial Viruses | 1 | 1998 | 171 | 0.040 |
Why?
|
| Respiratory Sounds | 1 | 1998 | 95 | 0.040 |
Why?
|
| Bronchiolitis | 1 | 1998 | 126 | 0.040 |
Why?
|
| Cost Savings | 1 | 1998 | 123 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2016 | 6100 | 0.040 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 1998 | 254 | 0.040 |
Why?
|
| Egg Yolk | 1 | 1996 | 7 | 0.040 |
Why?
|
| Egg White | 1 | 1996 | 9 | 0.040 |
Why?
|
| Scholarly Communication | 1 | 2017 | 19 | 0.040 |
Why?
|
| Virus Activation | 1 | 2018 | 228 | 0.040 |
Why?
|
| Disease Reservoirs | 1 | 1996 | 42 | 0.040 |
Why?
|
| Income | 1 | 2017 | 222 | 0.040 |
Why?
|
| Knowledge | 1 | 2016 | 52 | 0.040 |
Why?
|
| Haemophilus Vaccines | 1 | 1996 | 40 | 0.040 |
Why?
|
| Injections, Intravenous | 1 | 1997 | 573 | 0.040 |
Why?
|
| Muscle Weakness | 1 | 1997 | 116 | 0.040 |
Why?
|
| Anemia | 2 | 2013 | 689 | 0.030 |
Why?
|
| Administration, Topical | 1 | 2016 | 257 | 0.030 |
Why?
|
| Transportation | 1 | 2016 | 50 | 0.030 |
Why?
|
| Logic | 1 | 2015 | 10 | 0.030 |
Why?
|
| Decision Making | 1 | 2004 | 1287 | 0.030 |
Why?
|
| Accreditation | 1 | 2016 | 126 | 0.030 |
Why?
|
| Oral Hygiene | 1 | 2015 | 20 | 0.030 |
Why?
|
| Social Stigma | 1 | 2016 | 73 | 0.030 |
Why?
|
| Osteomyelitis | 1 | 1998 | 236 | 0.030 |
Why?
|
| Telephone | 1 | 1996 | 163 | 0.030 |
Why?
|
| Psychomotor Performance | 1 | 1997 | 233 | 0.030 |
Why?
|
| Zidovudine | 1 | 1995 | 40 | 0.030 |
Why?
|
| Infant, Premature, Diseases | 1 | 1998 | 245 | 0.030 |
Why?
|
| Virus Diseases | 1 | 1999 | 398 | 0.030 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 1 | 2015 | 23 | 0.030 |
Why?
|
| Religion | 1 | 2016 | 91 | 0.030 |
Why?
|
| Physical Examination | 1 | 1997 | 299 | 0.030 |
Why?
|
| Cultural Characteristics | 1 | 2015 | 70 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2011 | 29902 | 0.030 |
Why?
|
| Poultry Products | 1 | 1995 | 1 | 0.030 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 1998 | 211 | 0.030 |
Why?
|
| Measles | 1 | 1995 | 36 | 0.030 |
Why?
|
| Efficiency | 1 | 2015 | 99 | 0.030 |
Why?
|
| Disease Notification | 1 | 1995 | 11 | 0.030 |
Why?
|
| Sexually Transmitted Diseases, Bacterial | 1 | 1994 | 3 | 0.030 |
Why?
|
| Rheumatic Heart Disease | 1 | 2015 | 44 | 0.030 |
Why?
|
| United States Food and Drug Administration | 1 | 2016 | 332 | 0.030 |
Why?
|
| Adhesins, Bacterial | 1 | 2015 | 85 | 0.030 |
Why?
|
| Models, Educational | 1 | 2015 | 95 | 0.030 |
Why?
|
| Sexually Transmitted Diseases, Viral | 1 | 1994 | 6 | 0.030 |
Why?
|
| Bleomycin | 1 | 2016 | 467 | 0.030 |
Why?
|
| Coagulase | 1 | 1994 | 29 | 0.030 |
Why?
|
| Patient Education as Topic | 1 | 1999 | 748 | 0.030 |
Why?
|
| Vaccines, Synthetic | 1 | 1996 | 355 | 0.030 |
Why?
|
| Bronchoscopy | 1 | 1998 | 474 | 0.030 |
Why?
|
| DNA, Bacterial | 2 | 2007 | 558 | 0.030 |
Why?
|
| Career Choice | 1 | 2016 | 232 | 0.030 |
Why?
|
| Truth Disclosure | 1 | 2016 | 180 | 0.030 |
Why?
|
| Immunization | 1 | 1996 | 397 | 0.030 |
Why?
|
| Vancomycin | 1 | 1996 | 273 | 0.030 |
Why?
|
| Survival Rate | 2 | 2007 | 12221 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 2002 | 1879 | 0.030 |
Why?
|
| Staphylococcus | 1 | 1994 | 86 | 0.030 |
Why?
|
| Complement C3 | 1 | 1994 | 78 | 0.030 |
Why?
|
| Length of Stay | 2 | 1998 | 1900 | 0.030 |
Why?
|
| Benzoxazines | 1 | 2013 | 27 | 0.030 |
Why?
|
| Tobacco Smoke Pollution | 1 | 1995 | 105 | 0.030 |
Why?
|
| Alkynes | 1 | 2013 | 29 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 1998 | 945 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 1998 | 2307 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 15862 | 0.030 |
Why?
|
| Bacteriological Techniques | 1 | 1994 | 121 | 0.030 |
Why?
|
| Streptococcus agalactiae | 1 | 1994 | 107 | 0.030 |
Why?
|
| Cyclopropanes | 1 | 2013 | 88 | 0.030 |
Why?
|
| Dexamethasone | 1 | 1998 | 1450 | 0.030 |
Why?
|
| Aged | 4 | 2011 | 70117 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 1996 | 538 | 0.030 |
Why?
|
| Risk | 1 | 2017 | 1972 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 1995 | 829 | 0.030 |
Why?
|
| Monocytes | 1 | 1997 | 788 | 0.030 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2013 | 33 | 0.030 |
Why?
|
| Prosthesis-Related Infections | 1 | 2015 | 232 | 0.030 |
Why?
|
| Neuropsychological Tests | 1 | 1997 | 1178 | 0.030 |
Why?
|
| Pregnancy | 3 | 2012 | 7573 | 0.030 |
Why?
|
| Quality Improvement | 1 | 2020 | 851 | 0.030 |
Why?
|
| Community Networks | 1 | 2012 | 45 | 0.030 |
Why?
|
| Catheter-Related Infections | 1 | 2015 | 270 | 0.030 |
Why?
|
| Food, Formulated | 1 | 2012 | 50 | 0.030 |
Why?
|
| Community Health Workers | 1 | 2012 | 57 | 0.030 |
Why?
|
| Combined Modality Therapy | 2 | 2015 | 8865 | 0.030 |
Why?
|
| Dysgammaglobulinemia | 1 | 1991 | 4 | 0.030 |
Why?
|
| IgG Deficiency | 1 | 1991 | 3 | 0.030 |
Why?
|
| Vincristine | 1 | 2016 | 1511 | 0.030 |
Why?
|
| Anemia, Sickle Cell | 1 | 1995 | 339 | 0.030 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 1 | 1993 | 123 | 0.030 |
Why?
|
| Antibodies, Viral | 1 | 1998 | 1320 | 0.030 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 1991 | 47 | 0.030 |
Why?
|
| Emotions | 1 | 2015 | 562 | 0.030 |
Why?
|
| Receptors, Fc | 1 | 1991 | 69 | 0.030 |
Why?
|
| Anti-Infective Agents | 1 | 1995 | 446 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2002 | 3719 | 0.020 |
Why?
|
| Diagnostic Tests, Routine | 1 | 1993 | 173 | 0.020 |
Why?
|
| Heart Valve Prosthesis | 1 | 2015 | 386 | 0.020 |
Why?
|
| Patient Safety | 1 | 2016 | 649 | 0.020 |
Why?
|
| Complement System Proteins | 1 | 1991 | 139 | 0.020 |
Why?
|
| Esophageal Diseases | 1 | 2011 | 69 | 0.020 |
Why?
|
| Immunoglobulins | 1 | 1991 | 266 | 0.020 |
Why?
|
| Meningitis | 1 | 2011 | 112 | 0.020 |
Why?
|
| Cefuroxime | 2 | 2001 | 15 | 0.020 |
Why?
|
| Logistic Models | 2 | 2012 | 3441 | 0.020 |
Why?
|
| Child Mortality | 1 | 2010 | 21 | 0.020 |
Why?
|
| Disease Management | 1 | 2016 | 1052 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 1994 | 1021 | 0.020 |
Why?
|
| Nutritional Status | 1 | 2012 | 337 | 0.020 |
Why?
|
| Patient Care Team | 1 | 2015 | 795 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 1998 | 2594 | 0.020 |
Why?
|
| Prenatal Care | 1 | 2012 | 325 | 0.020 |
Why?
|
| Remission Induction | 1 | 2016 | 3569 | 0.020 |
Why?
|
| Health Services Research | 1 | 2011 | 233 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1997 | 4938 | 0.020 |
Why?
|
| Cell Separation | 1 | 1991 | 612 | 0.020 |
Why?
|
| Pleural Effusion | 2 | 2002 | 201 | 0.020 |
Why?
|
| Candidiasis | 1 | 2011 | 262 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 1991 | 1618 | 0.020 |
Why?
|
| Antiviral Agents | 1 | 1995 | 1230 | 0.020 |
Why?
|
| Escherichia coli | 1 | 1994 | 1203 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 2013 | 846 | 0.020 |
Why?
|
| Mouth Neoplasms | 1 | 2013 | 713 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 2 | 1996 | 2403 | 0.020 |
Why?
|
| Lung | 1 | 1998 | 3151 | 0.020 |
Why?
|
| Odds Ratio | 2 | 2007 | 2316 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2012 | 1945 | 0.020 |
Why?
|
| Cause of Death | 1 | 2010 | 752 | 0.020 |
Why?
|
| Blood Chemical Analysis | 1 | 2007 | 118 | 0.020 |
Why?
|
| Deoxyribonucleases, Type II Site-Specific | 1 | 2006 | 68 | 0.020 |
Why?
|
| Diagnosis, Differential | 2 | 1998 | 4744 | 0.020 |
Why?
|
| Prednisone | 1 | 2009 | 984 | 0.020 |
Why?
|
| Infant, Premature | 1 | 1991 | 787 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2009 | 461 | 0.020 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 2006 | 362 | 0.020 |
Why?
|
| Hearing Loss | 1 | 2006 | 153 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 1991 | 3033 | 0.020 |
Why?
|
| Methyltransferases | 1 | 2006 | 148 | 0.020 |
Why?
|
| Debridement | 1 | 2005 | 123 | 0.020 |
Why?
|
| Patient Isolation | 1 | 2004 | 25 | 0.020 |
Why?
|
| Heart Defects, Congenital | 1 | 2015 | 1697 | 0.010 |
Why?
|
| Device Removal | 1 | 2005 | 337 | 0.010 |
Why?
|
| Meat Products | 1 | 2002 | 6 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 2006 | 1471 | 0.010 |
Why?
|
| Lung Abscess | 1 | 2002 | 13 | 0.010 |
Why?
|
| Food Contamination | 1 | 2002 | 22 | 0.010 |
Why?
|
| Empyema | 1 | 2002 | 28 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2017 | 13658 | 0.010 |
Why?
|
| Ribotyping | 1 | 2002 | 48 | 0.010 |
Why?
|
| Interviews as Topic | 1 | 2004 | 497 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2013 | 2967 | 0.010 |
Why?
|
| Child, Hospitalized | 1 | 2002 | 62 | 0.010 |
Why?
|
| Bacterial Typing Techniques | 1 | 2002 | 139 | 0.010 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2003 | 202 | 0.010 |
Why?
|
| Age of Onset | 1 | 2003 | 827 | 0.010 |
Why?
|
| Necrosis | 1 | 2002 | 580 | 0.010 |
Why?
|
| Leukocytosis | 1 | 2000 | 112 | 0.010 |
Why?
|
| Acute Disease | 1 | 2005 | 2422 | 0.010 |
Why?
|
| Phylogeny | 1 | 2002 | 826 | 0.010 |
Why?
|
| Nasal Lavage Fluid | 1 | 1998 | 19 | 0.010 |
Why?
|
| Benzophenoneidum | 1 | 1998 | 1 | 0.010 |
Why?
|
| Empyema, Pleural | 1 | 1998 | 48 | 0.010 |
Why?
|
| Rhodamines | 1 | 1998 | 49 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2011 | 9244 | 0.010 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 1998 | 189 | 0.010 |
Why?
|
| Nocardia Infections | 1 | 1998 | 34 | 0.010 |
Why?
|
| Deafness | 1 | 1998 | 82 | 0.010 |
Why?
|
| Skin Neoplasms | 1 | 2013 | 4654 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1996 | 418 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2006 | 2819 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1998 | 1489 | 0.010 |
Why?
|
| Disease Transmission, Infectious | 1 | 1995 | 94 | 0.010 |
Why?
|
| Radiography | 1 | 1998 | 1904 | 0.010 |
Why?
|
| Rural Population | 1 | 1995 | 281 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 1994 | 684 | 0.010 |
Why?
|
| Phenotype | 1 | 2002 | 6295 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 1998 | 4892 | 0.010 |
Why?
|